2019
The federal plan for health science and technology’s response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked
Becker JB, Mazure CM. The federal plan for health science and technology’s response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked. Biology Of Sex Differences 2019, 10: 3. PMID: 30616693, PMCID: PMC6322277, DOI: 10.1186/s13293-018-0215-5.Peer-Reviewed Original ResearchConceptsOpioid crisisClinical care providersCurrent opioid epidemicNeurobiology of painGender-specific treatmentGender differencesNeonatal exposureOpioid useOpioid epidemicOpioid addictionCare providersEpidemiological dataPrevention strategiesHealth SciencesGender-based treatmentSuccessful responseSexPrevention implicationsReportTreatmentAddictionFurther researchResponseOpioidsPain
1998
Pretreatment plasma HVA predicts neuroleptic response in manic psychosis
Mazure C, Bowers M. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. Journal Of Affective Disorders 1998, 48: 83-86. PMID: 9495606, DOI: 10.1016/s0165-0327(97)00159-6.Peer-Reviewed Original ResearchAcute Neuroleptic Treatment in Elderly Patients Without Dementia
Mazure C, Nelson J, Jatlow P, Bowers M. Acute Neuroleptic Treatment in Elderly Patients Without Dementia. American Journal Of Geriatric Psychiatry 1998, 6: 221-229. PMID: 9659955, DOI: 10.1097/00019442-199800630-00005.Peer-Reviewed Original ResearchConceptsNon-elderly adultsElderly patientsNeuroleptic treatmentAcute responseLow dosesLow-dose neuroleptic treatmentAcute neuroleptic treatmentAdverse effectsHigh-dose treatmentLow-dose treatmentDrug blood levelsPrimary psychotic illnessInitial doseBlood levelsPsychotic illnessEffective treatmentPatientsDose ratioLonger durationTreatmentLower ratesDosesAdultsResponseNeuroleptics
1992
Drug-responsive symptoms during early neuroleptic treatment
Mazure C, Nelson J, Jatlow P, Bowers M. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Research 1992, 41: 147-154. PMID: 1574541, DOI: 10.1016/0165-1781(92)90106-d.Peer-Reviewed Original ResearchConceptsDrug responseEarly drug responseDays of treatmentIdentification of symptomsNeuroleptic treatmentSerum concentrationsNeuroleptic drugsNeurochemical mechanismsPositive symptomsSymptomsProgressive phaseDrug actionConceptual disorganizationMultiple regression analysisRegression analysisTreatmentPsychosisSeverityHallucinationsResponse
1990
Value of the DST for predicting response of patients with major depression to hospitalization and desipramine
Nelson JC, Mazure CM, Jatlow PI. Value of the DST for predicting response of patients with major depression to hospitalization and desipramine. American Journal Of Psychiatry 1990, 147: 1488-1492. PMID: 2221161, DOI: 10.1176/ajp.147.11.1488.Peer-Reviewed Original ResearchConceptsDexamethasone suppression testResponse of patientsMajor depressionNegative dexamethasone suppression testPositive dexamethasone suppression testWeeks of hospitalizationNonpsychotic major depressionPlasma levelsSuppression testRate of responseAntidepressant drugsDrug treatmentPatientsHospitalizationDesipraminePrior reportsDepressionResponsePrior studiesPlaceboFindingsTrialsWeeksDoes melancholia predict response in major depression?
Nelson J, Mazure C, Jatlow P. Does melancholia predict response in major depression? Journal Of Affective Disorders 1990, 18: 157-165. PMID: 2139060, DOI: 10.1016/0165-0327(90)90032-4.Peer-Reviewed Original Research
1988
Antidepressant activity of 2‐hydroxydesipramine
Nelson J, Mazure C, Jatlow P. Antidepressant activity of 2‐hydroxydesipramine. Clinical Pharmacology & Therapeutics 1988, 44: 283-288. PMID: 3416551, DOI: 10.1038/clpt.1988.151.Peer-Reviewed Original ResearchConceptsPlasma levelsOH-DMIAntidepressant activityDSM-III major depressionDMI levelsSteady-state plasma levelsWeeks of hospitalizationDrug plasma levelsFixed-dose protocolTotal drug levelsMajor depressionDrug levelsParent drugMeasure of responseTrialsResponsePrior studiesHospitalizationLevelsMedicationsPatientsInpatientsNonpsychoticDoseWeeks